Assessment of potential measures in models of progression in Alzheimer disease

Neurology

Volumn 75, Issue 14, 2010, Pages 1256-1262

  McLaughlin, T ^a   Buxton, M ^b   Mittendorf, T ^c   Redekop, W ^d   Mucha, L ^e   Darba, J ^f   Jonsson, L ^g   Lacey, L ^h   Leibman, C ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b BRUNEL UNIVERSITY   (United Kingdom)

^c LEIBNIZ UNIVERSITY HANNOVER   (Germany)

^d ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^e PFIZER INC   (United States)

^f UNIVERSITY OF BARCELONA   (Spain)

^g i3 Innovus   (Sweden)

^h Janssen Alzheimer Immunotherapy   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CAREGIVER; CLINICAL ASSESSMENT; COGNITION; DISEASE COURSE; DISEASE MODEL; DISEASE SEVERITY; ECONOMIC ASPECT; FEMALE; FUNCTIONAL ASSESSMENT; HEALTH CARE COST; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; QUALITY OF LIFE INDEX; CLINICAL TRIAL; COGNITIVE DEFECT; DISABILITY; MENTAL HEALTH; MIDDLE AGED; MULTICENTER STUDY; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; STATISTICAL MODEL;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CAREGIVERS; COGNITION DISORDERS; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; MODELS, STATISTICAL; NEUROPSYCHOLOGICAL TESTS; QUALITY OF LIFE;

EID: 77958194342     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181f6133d     Document Type: Article

References (19)

1. Neumann PJ, Araki SS, Arcelus A, et al. Measuring Alzheimer's disease progression with transition probabilities. Neurology 2001;57:957-964.
2. Stewart A, Phillips R, Dempsey G. Pharmacotherapy for people with Alzheimer's disease: a Markov-cycle evaluation of five years' therapy using donepezil. Int Geriatr Psychiatry 1998;13:44-53.
3. Fenn P, Gray A. Estimating the long term cost savings from the treatment of Alzheimer's disease: a modeling approach. Pharmacoeconomics 1999;16:165-174.
4. Caro JJ, Getsios D, Migliaccio-Walle K, Raggio G, Ward A. Assessment of health economics in Alzheimer's Disease (AHEAD) based on need for full-time care. Neurology 2001;57:964-971.
5. Green C, Picot J, Loveman E, Takeda A, Kirby J, Clegg A. Modeling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease. Pharmacoeconomics 2005;23:1271-1282.
6. Cohen JT, Neumann PJ. Decision analytic models for Alzheimer's disease: state of the art and future directions. Alz-heimers Dement 2008;4:212-222.
7. Riepe MW, Mittendorf T, Forstl H, et al. Quality of life as an outcome in Alzheimer's disease and other dementias: obstacles and goals. BMC Neurol 2009;9:47.
8. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
9. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
10. Feldman HH, Woodward M. The staging and assessment of moderate to severe Alzheimer disease. Neurology 2005; 65(suppl 3):S10-S17.
11. Gauthier S, Gelinas I, Gauthier L. Functional disability in Alzheimer's disease. Int Psychogeriatr 1997;9(suppl 1): 163-165.
12. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-2414.
13. Cummings JL. The neuropsychiatric inventory: assessing psychopathology in dementia patients. Neurology 1997; 48(suppl 6):S10-S16.
14. Horsman J, Furlong W, Feeny D, Torrance G. The Health Utilities Index (HUI): concepts, measurement properties and applications. Health Qual Life Outcomes 2003;1:54.
15. Ware JE Jr, Gandek B, IQOLA Project Group. The SF-36 Health Survey: development and use in mental health research and IQOLA project. Int J Mental Health 1994;23: 49-73.
16. Logsdon RG, Gibbons LE, McCurry SM, Teri L. Assessing quality of life in older adults with cognitive impairment. Psychosom Med 2002;64:510-519.
17. Wimo A, Nordberg G. Validity and reliability of assessments of time: comparisons of direct observations and estimates of time by the use of the resource utilization in dementia (RUD)-instrument. Arch Gerontol Geriatr 2007;44:71-81.
18. Bowie P, Branton T, Holmes J. Should the Mini Mental State Examination be used to monitor dementia treatments? Lancet 1999;354:1527-1528.
19. Davey RJ, Jamieson S. The validity of using the Mini-Mental State Examination in NICE dementia guidelines. J Neurol Neurosurg Psychiatry 2004;75:343-344.